The Uromigos
The Uromigos
Advertisement
The UromigosThe Uromigos | February 19, 2025
Returning guest Dr. Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.
Listen Now
The UromigosThe Uromigos | February 19, 2025
Dr. Vincent Xu of Dana-Farber Cancer Institute discusses this emerging RCC biomarker and data from the Checkmate 214 trial.
The UromigosThe Uromigos | February 19, 2025
Returning guest Dr. Laurence Albiges discusses novel combos in refractory RCC and gives an update on COSMIC-313.
The UromigosThe Uromigos | February 19, 2025
Dr. Gopa Iyer of Memorial Sloan Kettering Cancer Center joins the show to discuss his initial results.
The UromigosThe Uromigos | February 14, 2025
Dr. Matt Galsky joins the show to discuss pathological complete response rates from the NIAGARA trial.
The UromigosThe Uromigos | February 14, 2025
Dr. Xinan Sheng joins the podcast to discuss the update of this trial and impressive pCR rates.
The UromigosThe Uromigos | February 13, 2025
Dr. Tanya Dorff discussed results of the STOPCAP trial from ASCO GU 2025, along with new data from TALAPRO-2.
The UromigosThe Uromigos | February 13, 2025
Dr. Neeraj Agarwal joins Tom and Brian for an in-depth look at important data from TALAPRO-2.
The UromigosThe Uromigos | February 7, 2025
Silke Gillessen joins Brian and Tom to discuss what to look forward to in prostate, bladder and RCC at ASCO GU 2025.
The UromigosThe Uromigos | February 6, 2025
David Braun, MD, PhD joins the show to discuss his Nature paper on a personalized RCC vaccine.
The UromigosThe Uromigos | January 30, 2025
Romain Banchereau, PhD, joins the show to discuss and debate this Cancer Cell paper on molecular subtypes in UC.
The UromigosThe Uromigos | January 13, 2025
Professor Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy in RCC tumors.
The UromigosThe Uromigos | January 10, 2025
Dr. Dorff reviews expectations for GU oncology updates in 2025.
The UromigosThe Uromigos | December 26, 2024
Dr. Silke Gillessen is joined by special guests to discuss the top highlights from 2024 in the prostate cancer field.
The UromigosThe Uromigos | December 26, 2024
Dr. Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer from 2024.
The UromigosThe Uromigos | December 26, 2024
Dr. David McDermott joins the podcast to review the top data from 2024 in the renal cell carcinoma field.
The UromigosThe Uromigos | December 19, 2024
Dr. Jim Brugarolas joins the podcast to discuss his talk from IKCS 2024 and the broad topic of resistance to HIF inhibitors.
The UromigosThe Uromigos | December 10, 2024
Dan Suzman, Deputy Oncology Director of the FDA, joins the podcast to discuss the Accelerated Approval process.
The UromigosThe Uromigos | December 9, 2024
Jonathan Rosenberg joins the podcast to discuss new updates on the phase 3 TROPiCS-04 study.
The UromigosThe Uromigos | December 3, 2024
Jakob Kather speaks with Brian and Tom on the use of artificial intelligence in the oncology landscape.
Advertisement
Advertisement
Advertisement